Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
CME Group (CME)
Q1 2013 Earnings Call
May 02, 2013 8:30 am ET
Phupinder S. Gill - Chief Executive Officer, Director, Member of Executive Committee and Member of Strategic Steering Committee
James E. Parisi - Chief Financial Officer and Senior Managing Director of Finance & Corporate Development
Derek Sammann - Senior Managing Director of Financial Products & Services
Bryan T. Durkin - Chief Operating Officer
Terrence A. Duffy - Executive Chairman, President, Chairman of Executive Committee and Member of Strategic Steering Committee
Kimberly S. Taylor - President of CME Clearing House Division
Richard H. Repetto - Sandler O'Neill + Partners, L.P., Research Division
Howard Chen - Crédit Suisse AG, Research Division
Christopher J. Allen - Evercore Partners Inc., Research Division
Alex Kramm - UBS Investment Bank, Research Division
Patrick J. O'Shaughnessy - Raymond James & Associates, Inc., Research Division
Jillian Miller - BMO Capital Markets U.S.
Daniel Thomas Fannon - Jefferies & Company, Inc., Research Division
Michael Carrier - BofA Merrill Lynch, Research Division
Christopher Harris - Wells Fargo Securities, LLC, Research Division
Niamh Alexander - Keefe, Bruyette, & Woods, Inc., Research Division
Brian Bedell - ISI Group Inc., Research Division
Gaston F. Ceron - Morningstar Inc., Research Division
…on our website. Also, note the final page of our earnings release contains a reconciliation to our GAAP results this quarter.
Now I'd like to turn the call over to Gill.
Phupinder S. Gill
Previous Statements by CME
» CME Group's Management Presents at Citigroup US Financial Services Conference (Transcript)
» CME Group Inc. Presents at 2013 Credit Suisse Financial Services Forum, Feb-12-2013 01:00 PM
» CME Group Management Discusses Q4 2012 Results - Earnings Call Transcript
We experienced a solid start of the year. First quarter average daily volume was 12.5 million contracts, up significantly from the 10.5 million contracts we averaged during the second half of last year. Open interest has jumped 18% year to date, up to 82.3 million contracts. Additionally, the first stage of the OTC clearing mandate was completed successfully, with cleared volumes roughly double what they were prior to the mandate.
Let me turn to the highlights of our core business. In the interest rate complex, we successfully grew volumes in open interest, up from the levels that we saw in the second half of 2012. Treasury volume has been particularly strong to start the year, with first quarter ADV of $3.4 million, up 24% compared to the same period last year. This included a Treasury futures monthly record of 3.8 million contracts in February, up 33% over the prior February, and we reached a daily all-time high of 10.1 million contracts on February 26.
Additionally, we've continued to successfully expand our options business with a record level of electronic trading of our 10-year Treasury note options of 54%, as well as generating 48% volume growth in our popular weekly Treasury options. Treasury options volume in February was the second highest month in our history. Overall, interest rate average daily volume was 5.7 million contracts in the first quarter of 2013 compared to 4.3 million during the second half of 2012.
Although the last 2 years have been challenging due to low volatility and low overall rates, we have invested in our interest rate complex through new product development to position it to strongly benefit once we come out of this difficult cycle.
In the intermediate and long term, we would expect an improving economy, the end to quantitative easing and increasing uncertainty around both the long and short ends of the curve, a large part of this for the franchise. This product line also stands to benefit from the migration of noncleared OTC interest rate swaps into clearinghouses and potentially, substitution of futures contracts for some of those OTC products. And CME Group's value proposition is significantly enhanced with the introduction of portfolio margining for both house and client accounts, creating powerful capital efficiencies for our global client base.
Looking at OTC, as I mentioned earlier, there has been a nice pickup in volume since Wave 1 of the CFTC clearing mandate kicked in on March 11, the first of a series of important dates for the industry. Since then, we have averaged 20 billion per day, which is nearly twice the amount we've cleared from the beginning of the year leading up to the mandate.
Interest rate swap open interest has also grown 44% to $1.4 trillion since the beginning of the mandate. Recently, 270 buy side firms have registered with CME for OTC clearing, and we are working closely with hundreds of firms and many intermediaries preparing for Phase 2 that begins on June 10. We continue to work to build liquidity in the deliverable swap futures contract, and we have 35,000 of open interest and several thousand contracts traded per day mainly by hedge funds asset managers, mortgage services and banks. Right now along with our FCMs and end customers, we are focused on on-boarding for Phase 2 of the mandate. Post June, we expect an increased focus on our entire suite of rate offerings, including call futures, the DSF product, as well as cleared swaps.
During March, we've successfully completed the first customer portfolio margining between cleared swaps and futures through one of our FCMs, and we expect 3 to 5 additional clearing members to provide this to end clients in a more scalable way later this quarter, driven by client demand.
The number of intermediaries automating this process should increase throughout the year. Our sales forces is increasingly hearing about the importance of capital efficiencies and our interest rate swap product suite offers the best opportunity to optimize deployed capital, leveraging our existing deep open interest across the U.S. yield curve.